Israel-based HealthTech VC aMoon leads this $11 million financing round, backed by 83North, Dell Technologies Capital and existing investor Kamet Ventures (Axa’s venture arm).
Ibex will use the funds to go through the development of its solution for other pathologies and start international expansion.
First deal closed by Clipperton in Israel.
Combining a unique dataset of millions of pathology slides and electronic medical records with state-of-the-art Artificial Intelligence technologies, Ibex developed breakthrough algorithms to confirm cancer diagnoses of tissue biopsies. Thanks to this new funding, Ibex will be able to expand its engineering team and extend its product offering to additional types of cancers while pushing forward its commercial development, getting the edge on its competitors.
